Company intelligence / Profile preview
Baylink Biosciences
Palo Alto, California, United Statesbaylinkbio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
Baylink Biosciences has presented promising preclinical data on its lead ADC candidate BLB‑101 targeting CLDN6/9+ tumors. The proprietary linker platform demonstrates improved stability, reduced off-target toxicity, and enables delivery of challenging payloads at high DAR. No clinical results yet; all data are preclinical as of May 2025.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)Degrader antibody conjugates (DACs)Dual payload ADCs
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Baylink Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Baylink Biosciences.